$AADI
Aadi Bioscience, Inc.

2024 Q3 Form 10-Q Financial Statement

#000162828024035636 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $7.212M $6.179M $6.202M
YoY Change 21.03% -0.37% 80.45%
Cost Of Revenue $804.0K $778.0K $656.0K
YoY Change 15.35% 18.6% 92.38%
Gross Profit $6.408M $5.401M $5.546M
YoY Change 21.78% -2.61% 79.13%
Gross Profit Margin 88.85% 87.41% 89.42%
Selling, General & Admin $7.186M $7.892M $11.78M
YoY Change -35.96% -32.98% 17.69%
% of Gross Profit 112.14% 146.12% 212.33%
Research & Development $9.997M $13.09M $13.32M
YoY Change -15.92% -1.67% 72.34%
% of Gross Profit 156.01% 242.42% 240.08%
Depreciation & Amortization $47.00K $50.00K $43.00K
YoY Change -6.0% 16.28% 59.26%
% of Gross Profit 0.73% 0.93% 0.78%
Operating Expenses $17.18M $20.99M $25.09M
YoY Change -25.65% -16.36% 41.5%
Operating Profit -$13.41M -$15.58M -$19.55M
YoY Change -24.85% -20.27% 6.45%
Interest Expense $867.0K $1.001M $58.00K
YoY Change 1394.83% 1625.86% 0.0%
% of Operating Profit
Other Income/Expense, Net $867.0K $1.001M $1.574M
YoY Change -43.96% -36.4% 1474.0%
Pretax Income -$12.55M -$14.58M -$17.97M
YoY Change -23.04% -18.85% -1.58%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.50M -$14.60M -$18.00M
YoY Change -23.31% -18.89% -1.64%
Net Earnings / Revenue -173.32% -236.28% -290.23%
Basic Earnings Per Share -$0.46 -$0.54 -$0.67
Diluted Earnings Per Share -$0.46 -$0.54 -$0.67
COMMON SHARES
Basic Shares Outstanding 24.61M shares 24.55M shares 24.44M shares
Diluted Shares Outstanding 27.04M shares 27.01M shares 26.88M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.62M $78.57M $134.9M
YoY Change -47.51% -41.75% 13.6%
Cash & Equivalents $30.54M $41.14M $68.16M
Short-Term Investments $32.08M $37.43M $66.73M
Other Short-Term Assets $2.688M $2.419M $2.901M
YoY Change -36.0% -16.61% 3.31%
Inventory $5.468M $6.098M $3.457M
Prepaid Expenses
Receivables $6.540M $5.920M $3.676M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $77.32M $93.01M $144.9M
YoY Change -41.82% -35.82% 16.56%
LONG-TERM ASSETS
Property, Plant & Equipment $5.982M $6.004M $3.005M
YoY Change 66.12% 99.8% 741.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.515M $1.629M $1.951M
YoY Change -20.85% -16.5% -14.84%
Total Long-Term Assets $8.383M $8.615M $6.305M
YoY Change 23.73% 36.64% 46.59%
TOTAL ASSETS
Total Short-Term Assets $77.32M $93.01M $144.9M
Total Long-Term Assets $8.383M $8.615M $6.305M
Total Assets $85.70M $101.6M $151.2M
YoY Change -38.64% -32.8% 17.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.374M $2.265M $2.898M
YoY Change -47.26% -21.84% -19.92%
Accrued Expenses $14.12M $13.75M $9.685M
YoY Change 20.33% 41.98% 11.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.81M $22.15M $13.00M
YoY Change -22.93% 70.41% 3.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $393.0K $682.0K $6.813M
YoY Change -56.33% -89.99% 6150.46%
Total Long-Term Liabilities $393.0K $682.0K $6.813M
YoY Change -56.33% -89.99% 6150.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.81M $22.15M $13.00M
Total Long-Term Liabilities $393.0K $682.0K $6.813M
Total Liabilities $16.83M $22.83M $19.81M
YoY Change -21.59% 15.25% -0.49%
SHAREHOLDERS EQUITY
Retained Earnings -$314.4M -$301.8M -$236.4M
YoY Change 24.42% 27.66% 35.24%
Common Stock $383.2M $380.7M $367.9M
YoY Change 3.32% 3.48% 29.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.87M $78.79M $131.4M
YoY Change
Total Liabilities & Shareholders Equity $85.70M $101.6M $151.2M
YoY Change -38.64% -32.8% 17.56%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$12.50M -$14.60M -$18.00M
YoY Change -23.31% -18.89% -1.64%
Depreciation, Depletion And Amortization $47.00K $50.00K $43.00K
YoY Change -6.0% 16.28% 59.26%
Cash From Operating Activities -$15.69M -$9.157M -$16.76M
YoY Change 31.27% -45.36% 56.32%
INVESTING ACTIVITIES
Capital Expenditures $188.0K $541.0K $689.0K
YoY Change -82.91% -21.48% -385.89%
Acquisitions
YoY Change
Other Investing Activities $5.273M -$3.030M $51.25M
YoY Change -61.68% -105.91%
Cash From Investing Activities $5.085M -$3.571M $50.56M
YoY Change -59.87% -107.06% -21079.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 87.00K 313.0K
YoY Change -100.0% -72.2% -459.77%
NET CHANGE
Cash From Operating Activities -15.69M -9.157M -16.76M
Cash From Investing Activities 5.085M -3.571M 50.56M
Cash From Financing Activities 0.000 87.00K 313.0K
Net Change In Cash -10.60M -12.64M 34.12M
YoY Change -1731.08% -137.05% -408.8%
FREE CASH FLOW
Cash From Operating Activities -$15.69M -$9.157M -$16.76M
Capital Expenditures $188.0K $541.0K $689.0K
Free Cash Flow -$15.88M -$9.698M -$17.45M
YoY Change 21.65% -44.41% 66.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Investment Income Interest
InvestmentIncomeInterest
2343000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3295000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14583000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17971000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14583000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1280000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
34819000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
22829000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
27228000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24614834 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24614834 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
380651000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
374129000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-27000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6202000 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7892000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11776000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13093000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13315000 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
778000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
656000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1430000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1185000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
90460000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2839000 usd
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-19000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
78791000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19545000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-35096000 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24554205 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24554205 shares
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0667
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
27000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301835000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268963000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
78791000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
105195000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101620000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132423000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6179000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
21763000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
25747000 usd
us-gaap Costs And Expenses
CostsAndExpenses
46628000 usd
us-gaap Costs And Expenses
CostsAndExpenses
48439000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15584000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-36370000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1061000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1635000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
58000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
58000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
116000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
116000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1001000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1574000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2224000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3176000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32872000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33194000 usd
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-19000 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-12000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-54000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
71000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14602000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17983000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32926000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33123000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27010013 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27010013 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26879089 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26879089 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26995356 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26995356 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
105195000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3589000 usd
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-35000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-18289000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
94000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
83000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15223000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
145986000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3054000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
68000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
294000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32872000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33194000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6428000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5794000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
809000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2062000 usd
aadi Non Cash Interest Expense
NonCashInterestExpense
58000 usd
aadi Non Cash Interest Expense
NonCashInterestExpense
58000 usd
aadi Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
230000 usd
aadi Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
231000 usd
us-gaap Depreciation
Depreciation
99000 usd
us-gaap Depreciation
Depreciation
81000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
432000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1814000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-328000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1362000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2427000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-845000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-253000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-275000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-254000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-250000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4266000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6670000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28810000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38068000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2058000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
26555000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
23052000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
92000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6984000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
66890000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
94000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
294000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
17000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
49000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
321000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21749000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29143000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62952000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39083000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41203000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68226000 usd
us-gaap Interest Paid Net
InterestPaidNet
115000 usd
us-gaap Interest Paid Net
InterestPaidNet
115000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
591000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
519000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301800000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14600000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18000000.0 usd
us-gaap Net Income Loss
NetIncomeLoss
-32900000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33200000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
78600000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. In the opinion of management, all adjustments that are considered necessary for fair presentation have been included. The most significant estimates in the Company’s condensed consolidated financial statements relate to gross-to-net accruals, share-based compensation expense and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and available-for-sale marketable debt securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. While the Company has not experienced any losses in such deposits, the recent failure of Silicon Valley Bank, at which the Company holds cash and cash equivalents in multiple accounts, exposed the Company to credit risk prior to the resolution by the Federal Deposit Insurance Corporation in a manner that fully protected all depositors. The Company has not experienced any losses on deposits since inception.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are derived from customers located in the United States. The Company performs ongoing credit evaluations of its customers and maintains allowances for potential credit losses on customers’ accounts when deemed necessary. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41139000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62888000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
64000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
64000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41203000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62952000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
100000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
200000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 usd
CY2024Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3989000 usd
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
4640000 usd
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1649000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1366000 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
460000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
421000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
6098000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
6427000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6373000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5072000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
369000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
270000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6004000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4802000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
50000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
43000 usd
us-gaap Depreciation
Depreciation
99000 usd
us-gaap Depreciation
Depreciation
81000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
77272000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
77245000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
108111000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
33000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
108138000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2107000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2504000 usd
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1272000 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1590000 usd
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2549000 usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3081000 usd
CY2024Q2 aadi Accrued Clinical Current
AccruedClinicalCurrent
1809000 usd
CY2023Q4 aadi Accrued Clinical Current
AccruedClinicalCurrent
1416000 usd
CY2024Q2 aadi Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
4677000 usd
CY2023Q4 aadi Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
4315000 usd
CY2024Q2 aadi Accrued Liabilities Other Sales Related Expenses Current
AccruedLiabilitiesOtherSalesRelatedExpensesCurrent
720000 usd
CY2023Q4 aadi Accrued Liabilities Other Sales Related Expenses Current
AccruedLiabilitiesOtherSalesRelatedExpensesCurrent
772000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
617000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
628000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13751000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14306000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
982000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1169000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
374000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
434000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
682000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
833000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1056000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1267000 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
115000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
115000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
230000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
231000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
254000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
250000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
259000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
320000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
231000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
280000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
109000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1199000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
143000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1056000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
374000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
682000 usd
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y5M12D
CY2024Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0758
CY2024Q2 aadi Royalties Were Accrued On Product Sales
RoyaltiesWereAccruedOnProductSales
500000 usd
CY2023Q2 aadi Royalties Were Accrued On Product Sales
RoyaltiesWereAccruedOnProductSales
500000 usd
aadi Royalties Were Accrued On Product Sales
RoyaltiesWereAccruedOnProductSales
900000 usd
aadi Royalties Were Accrued On Product Sales
RoyaltiesWereAccruedOnProductSales
900000 usd
CY2021Q1 aadi Upfront Payment For License Agreement
UpfrontPaymentForLicenseAgreement
14000000.0 usd
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14000000.0 usd
CY2021Q1 aadi Upfront Payment For License Agreement
UpfrontPaymentForLicenseAgreement
14000000.0 usd
CY2020Q4 aadi Amount Of Certain Development Regulatory And Sales Milestones Payments Eligible To Receive Under License Agreement
AmountOfCertainDevelopmentRegulatoryAndSalesMilestonesPaymentsEligibleToReceiveUnderLicenseAgreement
257000000 usd
CY2020Q4 aadi Right To Terminate License Agreement
RightToTerminateLicenseAgreement
P120D
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24614834 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24554205 shares
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 usd
CY2024Q2 aadi Common Stock Number Of Votes Per Common Share
CommonStockNumberOfVotesPerCommonShare
1 vote
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4579659 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.11
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M13D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1461715 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.87
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
590041 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.41
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5451333 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2478035 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.97
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y9M21D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5451333 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
16000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2839000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3054000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6428000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5794000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.27
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.95
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
29167 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
29167 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
40000 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.29
aadi Number Of Class Of Warrants Exercised
NumberOfClassOfWarrantsExercised
0 shares
aadi Share Based Compensation Arrangement By Share Based Payment Award Stock Plan Offering Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod
P6M
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 aadi Accrued Clinical And Contract Manufacturing Expense
AccruedClinicalAndContractManufacturingExpense
6500000 usd
CY2023Q4 aadi Accrued Clinical And Contract Manufacturing Expense
AccruedClinicalAndContractManufacturingExpense
5700000 usd
CY2024Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
4600000 usd
CY2024Q2 aadi Collaboration And Supply Agreement Expense
CollaborationAndSupplyAgreementExpense
500000 usd
CY2023Q2 aadi Collaboration And Supply Agreement Expense
CollaborationAndSupplyAgreementExpense
200000 usd
aadi Collaboration And Supply Agreement Expense
CollaborationAndSupplyAgreementExpense
700000 usd
aadi Collaboration And Supply Agreement Expense
CollaborationAndSupplyAgreementExpense
500000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001628280-24-035636-index-headers.html Edgar Link pending
0001628280-24-035636-index.html Edgar Link pending
0001628280-24-035636.txt Edgar Link pending
0001628280-24-035636-xbrl.zip Edgar Link pending
aadi-20240630.htm Edgar Link pending
aadi-20240630.xsd Edgar Link pending
aadi-20240630xex311.htm Edgar Link pending
aadi-20240630xex312.htm Edgar Link pending
aadi-20240630xex321.htm Edgar Link pending
aadi-20240630xex322.htm Edgar Link pending
aadi-20240630_cal.xml Edgar Link unprocessable
aadi-20240630_def.xml Edgar Link unprocessable
exhibit102.htm Edgar Link pending
exhibit103.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
aadi-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aadi-20240630_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aadi-20240630_pre.xml Edgar Link unprocessable